{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:56:52Z","timestamp":1792634212904,"version":"4.5.0"},"reference-count":44,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Fuzi-Gancao herb couple is one of the most common herb couples involved\nin the TCM formula, which was used for the treatment of chronic diseases. The herb couple\nhas a hepatoprotective effect. However, its main components and therapeutic mechanism are not\nyet clear. This study aims to elucidate the therapeutic effect and mechanism of the Fuzi-Gancao\nherb couple on NAFLD from animal experiments, network pharmacology, and molecular docking.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>60 Male C57BL\/6 mice (20 g \u00b1 2 g) were randomly divided into six groups including the\nblank group (n=10) and NALFD group (n=50). The mice of the NALFD group were fed with a\nhigh-fat diet for 20 weeks to establish the NAFLD model and the NALFD mice were randomly divided\ninto five groups including positive group (berberine), model group and F-G groups with\nthree dosages (0.257, 0.514, 0.771 g\/kg) (n=10). After 10 weeks of administration, the serum was\ncollected for the analysis of ALT, AST, LDL-c, HDL-c, and TC, and liver tissues were collected\nfor pathological analysis. The TCMAS database was used to collect the main components and targets\nof the Fuzi-Gancao herb couple. The GeneCards database was used to collect NAFLD-related\ntargets, and the key targets were obtained by intersecting with herbal targets. The diseasecomponent-\ntarget relationship diagram was constructed by Cytoscape 3.9.1. The obtained key targets\nwere imported into the String database to obtain the PPI network, and imported into the DAVID\ndatabase for KEGG pathway analysis and GO analysis. Finally, the key targets and key gene\nproteins were imported into Discovery Studio 2019 for molecular docking verification.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In this study, H-E staining indicated the pathological changes of liver tissue in Fuzi-\nGancao groups were significantly improved, and the levels of AST, ALT, TC, HDL-c, and LDL-c\nin serum of Fuzi-Gancao groups decreased in a dose-dependent manner, compared with the model\ngroup. 103 active components and 299 targets in the Fuzi-Gancao herb couple were confirmed in\nthe TCMSP database and 2062 disease targets in NAFLD were obtained. 142 key targets and 167\nsignal pathways were screened, such as the AGE-RAGE signaling pathway in diabetic complications,\nHIF-1 signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and so on. The\nmain bioactive ingredients of Fuzi-Gancao herb couple in the treatment of NAFLD are quercetin,\nkaempferol, naringenin, inermine, (R)-norcoclaurine, isorhamnetin, ignavine, 2,7-Dideacetyl-2,7-\ndibenzoyl-taxayunnanine F, glycyrol mainly involving IL6, AKT1, TNF, TP53, IL1B, VEGFA and\nother core targets. Molecular docking analysis indicated that there is a good affinity between the\nkey components and the key targets.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study preliminarily explained the main components and mechanism of the Fuzi-\nGancao herb couple in the treatment of NAFLD and provided an idea for subsequent research.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207326666230614102412","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T09:27:20Z","timestamp":1686821240000},"page":"773-785","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Effect and Mechanism Prediction of Fuzi-Gancao Herb\nCouple on Non-alcoholic Fatty Liver Disease (NAFLD) based on Network\nPharmacology and Molecular Docking"],"prefix":"10.2174","volume":"27","author":[{"given":"Kejia","family":"Liu","sequence":"first","affiliation":[{"name":"Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, General Hospital of Northern Theater Command, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Liaoning University, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science, Liaoning University, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"Loomba R.","year":"2021","unstructured":"Loomba R.; Friedman S.L.; Shulman G.I.; Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell  2021,184(10),2537-2564","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"Sanyal A.J.","year":"2019","unstructured":"Sanyal A.J.; Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol  2019,16(6),377-386","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/cells8101259","volume":"8","author":"Lee C.","year":"2019","unstructured":"Lee C.; Kim J.; Jung Y.; Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Cells  2019,8(10),1259","journal-title":"Cells"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"Younossi Z.M.","year":"2019","unstructured":"Younossi Z.M.; Golabi P.; de Avila L.; Paik J.M.; Srishord M.; Fukui N.; Qiu Y.; Burns L.; Afendy A.; Nader F.; The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol  2019,71(4),793-801","journal-title":"J Hepatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","volume":"17","author":"Noureddin M.","year":"2018","unstructured":"Noureddin M.; Sanyal A.J.; Pathogenesis of NASH: The impact of multiple pathways. Curr Hepatol Rep  2018,17(4),350-360","journal-title":"Curr Hepatol Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","volume":"49","author":"Ong J.P.","year":"2008","unstructured":"Ong J.P.; Pitts A.; Younossi Z.M.; Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol  2008,49(4),608-612","journal-title":"J Hepatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14209","volume":"39","author":"Pockros P.J.","year":"2019","unstructured":"Pockros P.J.; Fuchs M.; Freilich B.; Schiff E.; Kohli A.; Lawitz E.J.; Hellstern P.A.; Owens-Grillo J.; Van Biene C.; Shringarpure R.; MacConell L.; Shapiro D.; Cohen D.E.; CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int  2019,39(11),2082-2093","journal-title":"Liver Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2468-1253(19)30183-9","volume":"4","author":"Chan W.K.","year":"2019","unstructured":"Chan W.K.; Wong V.W.S.; A new bile acid treatment for non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol  2019,4(10),747-749","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.14309\/ajg.0000000000000058","volume":"114","author":"Cheung A.","year":"2019","unstructured":"Cheung A.; Figueredo C.; Rinella M.E.; Nonalcoholic fatty liver disease: Identification and management of high-risk patients. Am J Gastroenterol  2019,114(4),579-590","journal-title":"Am J Gastroenterol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"105849","DOI":"10.1016\/j.phrs.2021.105849","volume":"172","author":"Chen M.","year":"2021","unstructured":"Chen M.; Xie Y.; Gong S.; Wang Y.; Yu H.; Zhou T.; Huang F.; Guo X.; Zhang H.; Huang R.; Han Z.; Xing Y.; Liu Q.; Tong G.; Zhou H.; Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res  2021,172,105849","journal-title":"Pharmacol Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fphar.2020.00601","volume":"11","author":"Xu Y.","year":"2020","unstructured":"Xu Y.; Guo W.; Zhang C.; Chen F.; Tan H.Y.; Li S.; Wang N.; Feng Y.; Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application. Front Pharmacol  2020,11,601","journal-title":"Front Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrd1609","volume":"4","author":"Keith C.T.","year":"2005","unstructured":"Keith C.T.; Borisy A.A.; Stockwell B.R.; Multicomponent therapeutics for networked systems. Nat Rev Drug Discov  2005,4(1),71-78","journal-title":"Nat Rev Drug Discov"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.phymed.2009.10.010","volume":"17","author":"Zhao F.R.","year":"2010","unstructured":"Zhao F.R.; Mao H.P.; Zhang H.; Hu L.M.; Wang H.; Wang Y.F.; Yanagihara N.; Gao X.M.; Antagonistic effects of two herbs in Zuojin Wan, a traditional Chinese medicine formula, on catecholamine secretion in bovine adrenal medullary cells. Phytomedicine  2010,17(8-9),659-668","journal-title":"Phytomedicine"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jep.2012.07.033","volume":"143","author":"Wang S.","year":"2012","unstructured":"Wang S.; Hu Y.; Tan W.; Wu X.; Chen R.; Cao J.; Chen M.; Wang Y.; Compatibility art of traditional Chinese medicine: From the perspective of herb pairs. J Ethnopharmacol  2012,143(2),412-423","journal-title":"J Ethnopharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e43848","DOI":"10.1371\/journal.pone.0043848","volume":"7","author":"Shaw L.H.","year":"2012","unstructured":"Shaw L.H.; Lin L.C.; Tsai T.H.; HPLC-MS\/MS analysis of a traditional Chinese medical formulation of Bu-Yang-Huan-Wu-Tang and its pharmacokinetics after oral administration to rats. PLoS One  2012,7(8),e43848","journal-title":"PLoS One"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1076\/phbi.34.5.344.13245","volume":"34","author":"Middleton J.","year":"1996","unstructured":"Middleton J.; Md E.; Biological properties of plant flavonoids: An overview. Int J Pharmacogn  1996,34,344-348","journal-title":"Int J Pharmacogn"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4103\/pm.pm_141_16","volume":"13","author":"Fu X.","year":"2017","unstructured":"Fu X.; Lu R.; Zhao S.; Simultaneous quantitation of six aconitum alkaloids and three flavonoids in the herb couple of radix aconiti lateralis-radix glycyrrhizae (Fuzi\u2013Gancao) by UHPLC-ESI-MS\/MS. Pharmacogn Mag  2017,13(51),425-429","journal-title":"Pharmacogn Mag"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"6888","DOI":"10.3748\/wjg.v27.i40.6888","volume":"27","author":"Wang M.F.","year":"2021","unstructured":"Wang M.F.; Zhao S.S.; Thapa D.M.; Song Y.L.; Xiang Z.; Metabolomics of Fuzi-Gancao in CCl4 induced acute liver injury and its regulatory effect on bile acid profile in rats. World J Gastroenterol  2021,27(40),6888-6907","journal-title":"World J Gastroenterol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinre.2016.07.001","volume":"41","author":"Shin J.H.","year":"2017","unstructured":"Shin J.H.; Jung J.H.; Non-alcoholic fatty liver disease and flavonoids: Current perspectives. Clin Res Hepatol Gastroenterol  2017,41(1),17-24","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4554996","volume":"2022","author":"Song R.","year":"2022","unstructured":"Song R.; Qian H.; Wang Y.; Li Q.; Li D.; Chen J.; Yang J.; Zhong J.; Yang H.; Min X.; Xu H.; Yang Y.; Chen J.; Research progress on the cardiovascular protective effect of glucagon-like peptide-1 receptor agonists. J Diabetes Res  2022,2022,1-8","journal-title":"J Diabetes Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ptr.6486","volume":"33","author":"Yang H.","year":"2019","unstructured":"Yang H.; Yang T.; Heng C.; Zhou Y.; Jiang Z.; Qian X.; Du L.; Mao S.; Yin X.; Lu Q.; Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db\/db mice. Phytother Res  2019,33(12),3140-3152","journal-title":"Phytother Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.freeradbiomed.2016.11.037","volume":"102","author":"Porras D.","year":"2017","unstructured":"Porras D.; Nistal E.; Mart\u00ednez-Fl\u00f3rez S.; Pisonero-Vaquero S.; Olcoz J.L.; Jover R.; Gonz\u00e1lez-Gallego J.; Garc\u00eda-Mediavilla M.V.; S\u00e1nchez-Campos S.; Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radic Biol Med  2017,102,188-202","journal-title":"Free Radic Biol Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.fct.2018.02.019","volume":"114","author":"Zhu X.","year":"2018","unstructured":"Zhu X.; Xiong T.; Liu P.; Guo X.; Xiao L.; Zhou F.; Tang Y.; Yao P.; Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a\/XBP1s pathway. Food Chem Toxicol  2018,114,52-60","journal-title":"Food Chem Toxicol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1610751","volume":"2018","author":"Du W.","year":"2018","unstructured":"Du W.; An Y.; He X.; Zhang D.; He W.; Protection of kaempferol on oxidative stress-induced retinal pigment epithelial cell damage. Oxid Med Cell Longev  2018,2018,1-14","journal-title":"Oxid Med Cell Longev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1089\/jmf.2015.3457","volume":"18","author":"Lee B.","year":"2015","unstructured":"Lee B.; Kwon M.; Choi J.S.; Jeong H.O.; Chung H.Y.; Kim H.R.; Kaempferol isolated from Nelumbo nucifera inhibits lipid accumulation and increases fatty acid oxidation signaling in adipocytes. J Med Food  2015,18(12),1363-1370","journal-title":"J Med Food"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jnutbio.2015.03.005","volume":"26","author":"Hoang M.H.","year":"2015","unstructured":"Hoang M.H.; Jia Y.; Mok B.; Jun H.; Hwang K.Y.; Lee S.J.; Kaempferol ameliorates symptoms of metabolic syndrome by regulating activities of liver X receptor-\u03b2. J Nutr Biochem  2015,26(8),868-875","journal-title":"J Nutr Biochem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1745-4514.2011.00561.x","volume":"36","author":"Jayachitra J.","year":"2012","unstructured":"Jayachitra J.; Nalini N.; Effect of naringenin (citrus flavanone) on lipid profile in ethanol\u2010induced toxicity in rats. J Food Biochem  2012,36(4),502-511","journal-title":"J Food Biochem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1389201019666180514170122","volume":"19","author":"Zobeiri M.","year":"2018","unstructured":"Zobeiri M.; Belwal T.; Parvizi F.; Naseri R.; Farzaei M.H.; Nabavi S.F.; Sureda A.; Nabavi S.M.; Naringenin and its nano-formulations for fatty liver: cellular modes of action and clinical perspective. Curr Pharm Biotechnol  2018,19(3),196-205","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"6254340","DOI":"10.1155\/2018\/6254340","volume":"16","author":"Xie X.","year":"2018","unstructured":"Xie X.; Yan D.; Li H.; Zhu Q.; Li J.; Fang Y.P.; Cheung C. W.; Irwin M. G.; Xia Z.; Lian Q.; Enhancement of adiponectin ameliorates nonalcoholic fatty liver disease via inhibition of FoxO1 in type I diabetic rats. J Diabetes Res  2018,16(2018),6254340","journal-title":"J Diabetes Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e12731","DOI":"10.1111\/cpr.12731","volume":"53","author":"Wu H.","year":"2020","unstructured":"Wu H.; Chen G.; Wang J.; Deng M.; Yuan F.; Gong J.; TIM\u20104 interference in Kupffer cells against CCL4\u2010induced liver fibrosis by mediating Akt1\/Mitophagy signalling pathway. Cell Prolif  2020,53(1),e12731","journal-title":"Cell Prolif"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/apm.12696","volume":"125","author":"Hendy O.M.","year":"2017","unstructured":"Hendy O.M.; Elsabaawy M.M.; Aref M.M.; Khalaf F.M.; Oda A.M.A.; El Shazly H.M.; Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. Acta Pathol Microbiol Scand Suppl  2017,125(7),607-613","journal-title":"Acta Pathol Microbiol Scand Suppl"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/nu9040387","volume":"9","author":"Kitade H.","year":"2017","unstructured":"Kitade H.; Chen G.; Ni Y.; Ota T.; Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients  2017,9(4),387","journal-title":"Nutrients"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","volume":"18","author":"Braunersreuther V.","year":"2012","unstructured":"Braunersreuther V.; Viviani G.L.; Mach F.; Montecucco F.; Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol  2012,18(8),727-735","journal-title":"World J Gastroenterol"},{"key":"ref=34","first-page":"699","volume":"33","author":"Weijie Z.","year":"2017","unstructured":"Weijie Z.; Hong Z.; Research advances in IL-6-mediated immunoinflammatory response and its relationship to disease. Cell Mol Immunol  2017,33,699-703","journal-title":"Cell Mol Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/bph.14095","volume":"175","author":"Wang W.","year":"2018","unstructured":"Wang W.; Zhao J.; Gui W.; Sun D.; Dai H.; Xiao L.; Chu H.; Du F.; Zhu Q.; Schnabl B.; Huang K.; Yang L.; Hou X.; Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol  2018,175(3),469-484","journal-title":"Br J Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e0149948","DOI":"10.1371\/journal.pone.0149948","volume":"11","author":"Yao L.","year":"2016","unstructured":"Yao L.; Abe M.; Kawasaki K.; Akbar S.M.F.; Matsuura B.; Onji M.; Hiasa Y.; Characterization of liver monocytic myeloid-derived suppressor cells and their role in a murine model of non-alcoholic fatty liver disease. PLoS One  2016,11(2),e0149948","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1053\/j.gastro.2014.01.061","volume":"146","author":"Yang L.","year":"2014","unstructured":"Yang L.; Kwon J.; Popov Y.; Gajdos G.B.; Ordog T.; Brekken R.A.; Mukhopadhyay D.; Schuppan D.; Bi Y.; Simonetto D.; Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology  2014,146,1339-1350.e1","journal-title":"Gastroenterology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e35143","DOI":"10.1371\/journal.pone.0035143","volume":"7","author":"Patel R.","year":"2012","unstructured":"Patel R.; Baker S.S.; Liu W.; Desai S.; Alkhouri R.; Kozielski R.; Mastrandrea L.; Sarfraz A.; Cai W.; Vlassara H.; Patel M.S.; Baker R.D.; Zhu L.; Effect of dietary advanced glycation end products on mouse liver. PLoS One  2012,7(4),e35143","journal-title":"PLoS One"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","volume":"2","author":"Ott C.","year":"2014","unstructured":"Ott C.; Jacobs K.; Haucke E.; Navarrete Santos A.; Grune T.; Simm A.; Role of advanced glycation end products in cellular signaling. Redox Biol  2014,2,411-429","journal-title":"Redox Biol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.20045","volume":"39","author":"Zeng S.","year":"2004","unstructured":"Zeng S.; Feirt N.; Goldstein M.; Guarrera J.; Ippagunta N.; Ekong U.; Dun H.; Lu Y.; Qu W.; Schmidt A.M.; Emond J.C.; Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology  2004,39(2),422-432","journal-title":"Hepatology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.148","volume":"98","author":"Litwinoff E.M.S.","year":"2015","unstructured":"Litwinoff E.M.S.; Hurtado del Pozo C.; Ramasamy R.; Schmidt A.M.; Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway. Clin Pharmacol Ther  2015,98(2),135-144","journal-title":"Clin Pharmacol Ther"},{"key":"ref=42","first-page":"562","volume":"25","author":"Ding M.M.","year":"2020","unstructured":"Ding M.M.; The role of IL-17 signaling pathway in the occurrence and development of alcohol-related liver cancer. Liver  2020,25,562","journal-title":"Liver"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/iub.1960","volume":"71","author":"Pan Y.","year":"2019","unstructured":"Pan Y.; Ren X.; Zhang Y.; Lv J.; Zeng Q.; Zhang H.; Yu Z.; IL-17A-mediated ERK1\/2\/p65 signaling pathway is associated with cell apoptosis after non-alcoholic steatohepatitis. IUBMB Life  2019,71(3),302-309","journal-title":"IUBMB Life"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/hep.26746","volume":"59","author":"Harley I.T.W.","year":"2014","unstructured":"Harley I.T.W.; Stankiewicz, T.E.; Giles, D.A.; Softic, S.; Flick, L.M.; Cappelletti, M.; Sheridan, R.; Xanthakos, S.A.; Steinbrecher, K.A.; Sartor, R.B.; Kohli, R.; Karp, C.L.; Divanovic, S. IL\u201017 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology  2014,59(5),1830-1839","journal-title":"Hepatology"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207326666230614102412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217968\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207326666230614102412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:46:35Z","timestamp":1713329195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217968\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207326666230614102412","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}